Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.66 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.99 - 1.995 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.66 | USD |
Spero Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
89.42M | 53.87M | - | 103.78M | 22.81M | 0.42 | 3.92 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spero Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.44 | 1.68 | 1.42 | 1.58 | 178,810 | 0.22 | 15.28% |
1 Month | 1.68 | 1.75 | 1.37 | 1.52 | 191,478 | -0.02 | -1.19% |
3 Months | 1.48 | 1.89 | 1.37 | 1.67 | 323,708 | 0.18 | 12.16% |
6 Months | 1.14 | 1.89 | 1.04 | 1.55 | 252,557 | 0.52 | 45.61% |
1 Year | 1.95 | 1.995 | 0.99 | 1.51 | 267,958 | -0.29 | -14.87% |
3 Years | 12.86 | 19.87 | 0.6801 | 2.34 | 962,715 | -11.20 | -87.09% |
5 Years | 11.34 | 23.639 | 0.6801 | 3.55 | 642,413 | -9.68 | -85.36% |
Spero Therapeutics Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |